Salmeterol

證據等級: L5

預測適應症: 7 個

Salmeterol: From Asthma/COPD Maintenance Therapy to Bronchitis

One-Sentence Summary

Salmeterol is a long-acting beta2-adrenergic agonist (LABA) bronchodilator, with published literature in this evidence pack documenting established use in asthma and chronic obstructive pulmonary disease (COPD). The TxGNN model predicts it may also be effective for Bronchitis (chronic bronchitis / COPD-associated bronchitis), with 16 clinical trials and 20 publications currently supporting this direction. Salmeterol is not currently registered with SAHPRA and has no marketed presence in South Africa.

Quick Overview

Item	Content
Original Indication	Data unavailable — SALMETEROL has no SAHPRA license on file (market status: not marketed); pharmacological literature in this pack documents it as a LABA bronchodilator used in asthma/COPD
Predicted New Indication	Bronchitis
TxGNN Prediction Score	99.92%
Evidence Level	L1
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data from DrugBank is not available (Data Gap DG002). Based on the literature evidence included in this pack, salmeterol is a selective, long-acting β2-adrenoceptor agonist (LABA) that activates bronchial smooth muscle β2 receptors, raises intracellular cAMP, and produces sustained bronchodilation (≥12 hours per dose). This mechanism is described repeatedly across the accompanying literature as the pharmacological basis for its use in asthma and COPD maintenance therapy (e.g., PMID 26051688, PMID 9257086, PMID 11419918).

Chronic bronchitis is one of the two classic phenotypes of COPD (the other being emphysema), and airflow obstruction plus impaired mucociliary clearance are central to its pathophysiology. Several trials and reviews in the evidence pack directly address salmeterol (often combined with fluticasone propionate) “for the treatment of COPD associated with chronic bronchitis” (PMID 15329047, PMID 16915216), and one mechanistic study specifically demonstrates that salmeterol improves mucociliary and cough clearance in patients with chronic bronchitis (PMID 15970448). This gives the TxGNN prediction a plausible, literature-supported pharmacological basis rather than being a purely data-driven artifact.

Because salmeterol lacks a SAHPRA license and formal DrugBank MOA/indication fields in this evidence pack (Data Gaps DG001, DG002), the “original indication” cannot be independently confirmed for the South African regulatory context — this should be resolved before any registration or prescribing decision is made.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00268177	Phase 3	Completed	130	Salmeterol/fluticasone propionate 50/500mcg BID vs placebo — bronchial anti-inflammatory activity in COPD (13-week, multicentre)
NCT02173691	Phase 3	Completed	623	Tiotropium vs salmeterol vs placebo — 6-month bronchodilator efficacy and safety in COPD
NCT04655508	Phase 3	Terminated	35	Fluticasone/salmeterol vs placebo for post-HSCT pediatric bronchiolitis obliterans syndrome with declining FEV1
NCT01332409	N/A	Completed	2000	Large post-marketing use investigation of salmeterol/fluticasone in COPD (chronic bronchitis/emphysema); pneumonia flagged as priority safety signal
NCT00064402	Phase 3	Completed	741	Bronchodilator effect and safety of long-acting beta agonist maintenance therapy over 12 weeks in COPD
NCT03333018	N/A	Completed	22155	Large European drug-utilisation post-authorisation safety study in new users of LAMA/LABA combination therapy for COPD
NCT01110200	Phase 4	Completed	639	Fluticasone/salmeterol vs salmeterol alone on rate of COPD exacerbations following hospitalization
NCT00064415	Phase 3	Completed	799	12-month chronic safety study of long-acting bronchodilator maintenance therapy in COPD
NCT00857766	Phase 4	Completed	249	Fluticasone/salmeterol DISKUS 250/50mcg BID vs placebo — effect on arterial stiffness in COPD
NCT00633217	Phase 4	Completed	247	Fluticasone/salmeterol HFA MDI 230/42mcg vs DISKUS 250/50mcg — efficacy/safety in COPD associated with chronic bronchitis

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15970448	2006	RCT	Pulmonary pharmacology & therapeutics	Salmeterol vs placebo improved mucociliary and cough clearance in mild-moderate chronic bronchitis patients
9916607	1998	RCT	Clinical therapeutics	Inhaled salmeterol vs oral theophylline — efficacy, tolerability, and quality-of-life in mild-to-moderate COPD
12970006	2003	RCT	Chest	Fluticasone/salmeterol combination vs placebo and individual agents — efficacy and safety in COPD
19124357	2008	Cohort/Comparative	Therapeutic advances in respiratory disease	One-year safety and tolerance evaluation of salmeterol vs arformoterol in COPD
25515181	2015	Guideline/Review	Basic & clinical pharmacology & toxicology	Finnish national COPD guideline — diagnosis, assessment, and pharmacotherapy of stable COPD
15329047	2004	Review	Drugs	Review of salmeterol/fluticasone propionate DPI, approved for COPD associated with chronic bronchitis
17196106	2006	Meta-analysis	Respiratory research	Meta-analysis of salmeterol vs placebo/usual therapy showing improved outcomes in COPD
16915216	2006	Patient experience trial	MedGenMed	Management of COPD associated with chronic bronchitis with inhaled fluticasone/salmeterol (ADVAIR DISKUS 250/50)
19210134	2009	Comparative/Database	Current medical research and opinion	Healthcare utilization and costs in chronic bronchitis patients initiating fluticasone/salmeterol vs other maintenance therapies
21225021	2010	Review	Drugs of today	Review of COPD/chronic bronchitis pathophysiology and inflammatory disease context relevant to bronchodilator therapy

South Africa Market Information

Salmeterol currently has no SAHPRA registration on file and is classified as Not Marketed in South Africa (0 licenses recorded in the evidence pack). No product, dosage form, or approved indication text is available to summarize.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

(Key warnings, contraindications, and drug-interaction data were not available in this evidence pack — this is flagged as a Blocking data gap, see below.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Bronchitis is supported by L1 evidence — multiple completed Phase 3 trials plus real-world/post-marketing studies (n up to 22,155) — and the underlying LABA mechanism is well documented in the literature for COPD/chronic bronchitis. Two other candidate indications in this evidence pack (asthma, obstructive lung disease) show comparably strong L1 evidence, reinforcing that salmeterol’s repurposing signal for obstructive airway disease is pharmacologically coherent rather than a model artifact. Conversely, low-scoring predictions in this pack (respiratory malformation, Rienhoff syndrome, asthma-related genetic susceptibility) have no mechanistic plausibility or supporting evidence and should be disregarded as knowledge-graph noise.

To proceed, the following is needed:

Resolve Blocking Data Gap DG001: obtain TFDA/SAHPRA-equivalent Professional Information (PI) warnings, precautions, and contraindications before any S1 safety evaluation
Resolve Data Gap DG002: confirm formal DrugBank MOA and original indication data to validate the mechanistic rationale independently of literature inference
Confirm SAHPRA registration pathway, since salmeterol is not currently marketed in South Africa (0 licenses)
Formal drug–drug interaction (DDI) review, since the current query returned no results
Clinical/regulatory review of whether “bronchitis” as a predicted indication is already substantively covered by existing international COPD labeling, to determine if this represents a true label-extension opportunity or a labeling/therapeutic-area clarification
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.